Combination of Osimertinib and Aspirin to Treat EGFR Mutation NSCLC Patients
Status:
COMPLETED
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
The third generation epidermal growth factor receptor-tyrosine Kinase InhibitorEGFR-TKI osimertinib has obvious curative effect for EGFR sensitive mutation and T790M mutation(PMID 27959700), but acquired drug resistance will occur. Previous studies show that apoptosis escape can lead to EGFR-TKI resistance.Osimertinib resistant cells show abnormal activation of PI3K/AKT/BIM activation(PMID 28765329). The classical drug aspirin can effectively decrease AKT phosphorylation and activate of BIM(PMID 28881293).So Investigators speculate that aspirin may decrease the PI3K/AKT/BIM signaling pathways, then promote osimertinib resistant cells apoptosis. The current study aims to evaluate the combination of aspirin and osimertinib in patients with EGFR/T790M mutations.
Phase:
PHASE2
Details
Lead Sponsor:
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University